Physicians' Academy for Cardiovascular Education
Educational slides on the emerging role of CETP inhibition in the management of cardiovascular disease
The benefit of the CETP inhibitor anacetrapib on major coronary events increases with longer follow-up, shown in a post-trial analysis of patients who had been randomized to anacetrapib compared to those on placebo in the REVEAL trial.
AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.
In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.
EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.
EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.
A Mendelian randomization study combined with metabolic biomarker analysis shows that CETP is an important causal determinant of HDL and VLDL concentration and composition.
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction
Mendelian randomisation suggests that CETP is not causally related to atherosclerosis in the general population, but only in men with normal glucose, HDL, and TG levels, and in women with ¬¬high CV risk or abnormal fasting glucose.
AHA 2017 A REVEAL-analysis shows that diabetes status does not affect the effect of anacetrapib on serious coronary events, and that anacetrapib slightly lowers the risk of new onset diabetes.
